Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;30(2):133-40.
doi: 10.1055/s-0033-1342954.

Surgical management of lung cancer

Adam Lackey  1 , Jessica S Donington  1
Affiliations
Review

Surgical management of lung cancer

Adam Lackey et al. Semin Intervent Radiol. 2013 Jun.

Abstract

Surgery serves an important role in the diagnosis, staging, and definitive management of non-small cell lung cancer (NSCLC). Resection is the primary mode of treatment for stage I and II NSCLC and an important component of the multimodality approach to stage IIIA disease. Standard resections include removal of the lobe involved with tumor and systematic evaluation of ipsilateral hilar and mediastinal lymph nodes. For early stage disease the evolving surgical treatment goals are aimed at decreasing morbidity and mortality through less invasive approaches including video-assisted thoracoscopic surgery and robotic approaches, and potentially decreasing the volume of lung removed for select patients with well-staged small peripheral tumors. For patients with locally advanced disease, ongoing research is focused on appropriately identifying patients who will most benefit from the addition of surgery to a multimodality regime and safely integrating resection with chemotherapy and radiotherapy.

Keywords: VATS; multimodality therapy; non-small cell lung cancer; robotic surgery; sublobar resection; surgery.

PubMed Disclaimer

References

    1. Rami-Porta R, Crowley J J, Goldstraw P. The revised TMN staging system for lung cancer. Ann Thor and Cardiovasc Surgery. 2009;15:4–9. - PubMed
    1. Winton T, Livingston R, Johnson D. et al.National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597. - PubMed
    1. Douillard J Y, Rosell R, De Lena M. et al.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–727. - PubMed
    1. Pignon J P, Tribodet H, Scagliotti G V. et al.Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. American Society of Clinical Oncology. 2008;26(21):3552–3559. - PubMed
    1. Wang K P, Brower R, Haponik E F, Siegelman S. Flexible transbronchial needle aspiration for staging of bronchogenic carcinoma. Chest. 1983;84(5):571–576. - PubMed